Profile data is unavailable for this security.
About the company
Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway than the most prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is a Phase III-ready, vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin. Tecarfarin was developed using a retrometabolic drug design process which targets a different metabolic pathway from the one targeted by the most prescribed anticoagulants. Tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.
- Revenue in USD (TTM)0.00
- Net income in USD-6.24m
- Incorporated2022
- Employees3.00
- LocationCadrenal Therapeutics Inc822 A1a North, Suite 300PONTE VEDRA 32082United StatesUSA
- Phone+1 (904) 300-0701
- Fax+1 (302) 655-5049
- Websitehttps://www.cadrenal.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CV Sciences Inc | 15.85m | -2.53m | 8.08m | 42.00 | -- | 3.22 | -- | 0.5096 | -0.0157 | -0.0157 | 0.098 | 0.0139 | 1.69 | 1.55 | 25.35 | 377,285.70 | -26.94 | -43.42 | -73.44 | -77.75 | 46.06 | 51.81 | -15.95 | -45.68 | 0.2530 | -- | 0.0114 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| Bioquest Corp | 0.00 | -507.41k | 10.01m | -- | -- | -- | -- | -- | -0.0485 | -0.0485 | 0.00 | -0.0467 | 0.00 | -- | -- | -- | -3,483.76 | -- | -- | -- | -- | -- | -- | -- | -- | -3.88 | -- | -- | -- | -- | 64.67 | -- | -- | -- |
| Healthy Extracts Inc | 2.88m | -1.37m | 10.18m | -- | -- | 25.45 | -- | 3.53 | -0.4725 | -0.4725 | 0.9845 | 0.1336 | 1.12 | 0.6654 | 28.03 | -- | -53.40 | -53.78 | -168.81 | -146.65 | 67.83 | 45.68 | -47.73 | -87.53 | 0.2059 | -0.9153 | 0.7131 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 10.24m | 233.00 | 0.0687 | 0.0011 | 2.65 | 0.1446 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 11.84m | 1.00 | -- | 0.0661 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 11.90m | 3.00 | -- | 0.4536 | -- | 27.59 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Cadrenal Therapeutics Inc | 0.00 | -6.24m | 12.37m | 3.00 | -- | 3.10 | -- | -- | -5.88 | -5.88 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -138.35 | -- | -173.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -17.24m | 12.44m | 2.00 | -- | 0.471 | -- | -- | -1.93 | -1.93 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | 0.5012 | -7.42 | 0.5333 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
| Guardion Health Sciences Inc | 6.43m | -5.93m | 14.04m | 9.00 | -- | 1.02 | -- | 2.18 | -4.61 | 4.97 | 5.04 | 10.71 | 0.4467 | 2.74 | 8.20 | 714,121.10 | -41.22 | -77.90 | -45.86 | -86.55 | 44.86 | 42.45 | -92.26 | -176.93 | 16.59 | -2.98 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| Aytu Biopharma Inc | 93.76m | -13.68m | 14.63m | 150.00 | -- | 0.4432 | -- | 0.1561 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
| Talphera Inc | 398.00k | -13.70m | 15.62m | 15.00 | -- | 1.23 | -- | 39.25 | -0.6353 | -0.6323 | 0.0185 | 0.7491 | 0.0187 | -- | -- | 26,533.33 | -64.37 | -22.60 | -78.11 | -28.55 | -- | -- | -3,443.22 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| DH Enchantment Inc | 100.00 | -173.19k | 16.09m | 1.00 | -- | -- | -- | 160,915.00 | -0.0002 | -0.0002 | 0.00 | -0.0012 | 0.0438 | 0.1493 | -- | 100.00 | -7,579.43 | -- | -- | -- | 0.00 | -- | -173,190.00 | -- | 0.0029 | -14.85 | -- | -- | -95.43 | -- | 59.53 | -- | -- | -- |
| Cara Therapeutics Inc | 11.00m | -111.08m | 16.56m | 55.00 | -- | 1.43 | -- | 1.51 | -2.04 | -2.04 | 0.2017 | 0.2115 | 0.1063 | 1.10 | 2.10 | 199,927.30 | -107.38 | -35.76 | -132.61 | -40.82 | 74.66 | -- | -1,010.20 | -162.10 | 4.48 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 17.20m | 91.00 | -- | 0.6521 | -- | 0.4551 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
Data as of Sep 20 2024. Currency figures normalised to Cadrenal Therapeutics Inc's reporting currency: US Dollar USD
2.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avantax Planning Partners, Inc.as of 30 Jun 2024 | 7.55k | 0.71% |
| Geode Capital Management LLCas of 30 Jun 2024 | 4.10k | 0.39% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 3.97k | 0.37% |
| Citadel Securities LLCas of 30 Jun 2024 | 3.64k | 0.34% |
| Virtu Americas LLCas of 30 Jun 2024 | 1.65k | 0.16% |
| Two Sigma Securities LLCas of 30 Jun 2024 | 1.06k | 0.10% |
| Biltmore Family Office LLCas of 30 Jun 2024 | 733.00 | 0.07% |
| Tower Research Capital LLCas of 30 Jun 2024 | 644.00 | 0.06% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 5.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
